Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression
- 76 Downloads
Targeting DNA repair mechanisms to induce apoptosis may be a promising strategy for breast cancer treatment. Olaparib is proved to have anticancer effect by inhibiting DNA repairing protein poly (ADP-ribose) polymerase (PARP). However, the cytotoxicity of olaparib is very limited to homologous recombination-proficient cells. This study aims to examine the effect and mechanism of olaparib treatment in breast cancer cell lines.
We investigated the cytotoxic effect of various doses of olaparib treatment to MCF-7 and ZR-75-1 cells in vitro. mRNA and protein levels of PARP and APE1 were examined by real-time PCR and western blot, respectively. APE1-deficient cell lines were created by RNA interference and used for in vitro cytotoxicity study as well as in vivo study.
2 µM or higher concentrations of olaparib lead to significant cell death and ROS production. Moreover, olaparib treatment not only inhibits PARP1, but also reduces the expression of APE1 in both mRNA and protein levels. Deficiency of APE1 resulted in increased sensitivity of MCF-7 and ZR-75-1 cells to olaparib treatment. In vivo study showed that reduction of APE1 significantly reduced the volume and weight of MCF-7 xenografted tumors when treated with olaparib, which suggests the synergistic function of inhibition of APE1 in promoting antitumor effects of olaparib treatment.
To acquire better benefits for HR-proficient breast cancer patients, developing chemotherapeutic drugs antagonize APE1 would be an effective strategy to improve the clinical outcome of PARP inhibitors.
KeywordsBreast cancer APE1 PARP1 Chemoresistance ROS Apoptosis
This work is funded by the Natural Science Foundation research project of Shaanxi Province, China (No. 2015JM8430), and the International Cooperative Project of Shaanxi province, China (No. 2016KW-008).
Compliance with ethical standards
Conflict of interest
The authors declare no conflict of interest.
Ethics approval and Informed consent
This article does not contain any studies with human participants or animals performed by any of the authors.
- 3.Edson MA, Li J (2015) Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. Breast Dis 26:223–225Google Scholar
- 4.Long JP, Ji ZW, Jiang K, Wang ZY, Meng GM (2015) miR-193b modulates resistance to doxorubicin in human breast cancer cells by downregulating MCL-1. Biomed Res Int 2015:375574Google Scholar
- 17.Puglisi F, Barbone F, Tell G et al (2002) Prognostic role of Ape/Ref-1 subcellular expression in stage I-III breast carcinomas. Oncol Rep 9:11–17Google Scholar
- 20.Bi H, Ming L, Cheng R, Luo H, Zhang Y, Jin Y (2016) Liver extracellular matrix promotes BM-MSCs hepatic differentiation and reversal of liver fibrosis through activation of integrin pathway. J Tissue Eng Regen Med 11:2685–2698Google Scholar
- 24.Choi YE, Battelli C, Watson J et al (2014) Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells. Oncotarget 5:2678–2687Google Scholar